Nasonex 0.05% - Nasal Spray 120 Doses

— seasonal and year-round allergic rhinitis in adults, adolescents and children from 2 years of age

— acute sinusitis or exacerbation of chronic sinusitis in adults (including the elderly) and adolescents from 12 years of age — as an auxiliary therapeutic agent in antibiotic treatment

— acute rhinosinusitis with mild to moderate symptoms without signs of severe bacterial infection in patients aged 12 years and older

— prevention of seasonal allergic rhinitis of moderate and severe course in adults and adolescents from 12 years of age (recommended 2-4 weeks before the expected start of the dusting season)

— nasal polyposis, accompanied by a violation of nasal breathing and smell in adults (from 18 years old)

Tradename :

Nasonex

Nasonex

Compound :

One dose contains : mometasone furoate (micronized, in the form of monohydrate) 50 mcg

Auxiliary components : dispersed cellulose (microcrystalline cellulose treated with sodium carmellose), glycerol, citric acid monohydrate, sodium citrate dihydrate, polysorbate 80, benzalkonium chloride (in the form of a 50% solution), purified water.

Properties : GCS for local use. It has anti-inflammatory and anti-allergic effects when used in doses that do not cause systemic effects.

Inhibits the release of inflammatory mediators. It increases the production of lipomodulin, which is an inhibitor of phospholipase A, which leads to a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of metabolic products of arachidonic acid — cyclic endoperoxides, prostaglandins.

It prevents the marginal accumulation of neutrophils, which reduces inflammatory exudate and production of lymphokines, inhibits the migration of macrophages, and leads to a decrease in the processes of infiltration and granulation.

Reduces inflammation by reducing the formation of chemotaxis substance (influence on late allergy reactions), inhibits the development of an immediate allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells).

Indications : — seasonal and year-round allergic rhinitis in adults, adolescents and children from 2 years of age

— acute sinusitis or exacerbation of chronic sinusitis in adults (including the elderly) and adolescents from 12 years of age — as an auxiliary therapeutic agent in antibiotic treatment

— acute rhinosinusitis with mild to moderate symptoms without signs of severe bacterial infection in patients aged 12 years and older

— prevention of seasonal allergic rhinitis of moderate and severe course in adults and adolescents from 12 years of age (recommended 2-4 weeks before the expected start of the dusting season)

— nasal polyposis, accompanied by a violation of nasal breathing and smell in adults (from 18 years old)

Dosage and administration : Adults (including elderly patients) and adolescents from 12 years of age.

The recommended preventive and therapeutic dose of the drug is 2 inhalations (50 mcg each) in each nostril 1 time / day.

Upon reaching the therapeutic effect for maintenance therapy, it is possible to reduce the dose to 1 inhalation in each nostril 1 time / day

If a reduction in the symptoms of the disease cannot be achieved by using the drug at the recommended therapeutic dose, the daily dose can be increased to 4 inhalations in each nostril 1 time / day (total daily dose — 400 mcg).

After reducing the symptoms of the disease, a dose reduction is recommended.

The onset of action of the drug is usually noted clinically within 12 hours after the first use of the drug.

Children aged 2 to 11 years: The recommended therapeutic dose is 1 inhalation (50 mcg) in each nostril 1 time / day (total daily dose is 100 mcg).

Contraindications : — hypersensitivity to the components of the drug

— recent surgery or trauma of the nose with damage to the mucous membrane of the nasal cavity — before the wound heals (due to the inhibitory effect of GCS on the healing process)

- Childhood and adolescence (with seasonal and year-round allergic rhinitis — up to 2 years, with acute sinusitis or exacerbation of chronic sinusitis — up to 12 years, with polyposis — up to 18 years) — due to the lack of relevant data.

Precautionary measures :

As with any long-term treatment, patients using Nasonex® nasal spray for several months or longer should be periodically examined by a doctor for possible changes in the nasal mucosa.

It is necessary to monitor patients receiving intranasal corticosteroids for a long time.

It is possible to develop growth retardation in children.

If growth retardation is detected in children, it is necessary to reduce the dose of intranasal corticosteroids to the lowest one, which allows effective control of symptoms.

In addition, the patient should be referred for consultation with a pediatrician.

If a local fungal infection of the nose or throat develops, discontinuation of Nasonex® nasal spray therapy and special treatment may be required.

Long-term irritation of the nasal and pharyngeal mucosa may also serve as a basis for discontinuing treatment with Nasonex® nasal spray.

Side effects : Nosebleeds, as well as discharge of blood-stained mucus or blood clots), burning sensation in the nose, irritation of the nasal mucosa, ulceration of the nasal mucosa.

Irritation of the pharynx (feeling of irritation of the mucous membrane of the pharynx).

Storage method : Store at a temperature not exceeding 25 degrees. After opening, store no longer than 2 months.

Package : The cardboard box holds a bottle — 120 doses.